Trial reportDrug design, development and therapy2025
Protective Effect of Dexmedetomidine Combined with Butorphanol on Perioperative Pulmonary Function in Patients Undergoing Laparoscopic Colorectal Cancer Resection: A Randomized, Double-Blind, 2 * 2 Factorial-Controlled Trial.
Trial report in Drug design, development and therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- The Optimal Dose of Butorphanol Combined with Ropivacaine for Supraclavicular Brachial Plexus Block in Patients Undergoing Upper Limb Fracture Surgery: A Randomized, Double-Blind, Controlled Clinical Trial.Drug design, development and therapy · 2026Trial
- Effects of Dexmedetomidine on Respiratory Mechanics in Elderly Patients Undergoing Laparoscopic Colorectal Tumor Resection: A Randomized Double-Blinded Trial.Drug design, development and therapy · 2026Trial
- Inflammatory biomarkers and physiological reserve: an explainable machine learning model for predicting postoperative pulmonary complications in elderly laparoscopic surgery.Frontiers in cellular and infection microbiology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Perioperative lung injury significantly affects the outcome of abdominal surgery. Research has shown that both dexmedetomidine and butorphanol can provide some perioperative lung protection. This study evaluated the protective effects of dexmedetomidine or metoprolol on lung function during laparoscopic resection of colorectal cancer and the potential synergistic effects of their combined use. Methods: A 6-month randomized double-blind placebo-controlled trial with a 2*2 factorial design was conducted at the Affiliated Hospital of Xuzhou Medical University. 176 patients undergoing laparoscopic colorectal cancer resection were randomized into four groups: control (C), dexmedetomidine (D), butorphanol (B), and combination dexmedetomidine + butorphanol (DB). The primary outcome was the arterial-alveolar oxygen partial pressure ratio (a/A ratio) at the end of the administration period (T1). Secondary outcomes included other lung function indices, incidence of postoperative pulmonary complications (PPCs) and other complications, the 15-item Recovery Quality Score (QoR-15) scores, and postoperative inflammatory marker levels. Results: Factorial analysis revealed significant main effects for Group D on the arterial alveolar oxygen partial pressure ratio (a/A ratio) at T1 (F=18.739, P < 0.001, η Conclusion: Dexmedetomidine combined with butorphanol enhances lung function in laparoscopic surgery patients by improving gas exchange, boosting ventilation efficiency, reducing inflammation, and decreasing postoperative pulmonary complications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.